Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

Similar articles for PubMed (Select 24534737)

1.

Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.

Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ.

Vaccine. 2014 Mar 26;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058. Epub 2014 Feb 15. Review.

PMID:
24534737
2.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

3.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
4.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

5.

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ.

Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

PMID:
17980938
6.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

7.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
8.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
9.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

PMID:
23306360
10.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28.

PMID:
23537397
11.

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.

Annemans L, Bresse X, Gobbo C, Papageorgiou M.

J Med Econ. 2010;13(3):537-51. doi: 10.3111/13696998.2010.502854.

PMID:
20707768
12.

Preventing herpes zoster through vaccination.

Gelb LD.

Ophthalmology. 2008 Feb;115(2 Suppl):S35-8. doi: 10.1016/j.ophtha.2007.10.015. Review.

PMID:
18243932
13.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573. Epub 2011 Jul 1.

14.

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.

Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.

Vaccine. 2012 Jan 11;30(3):675-84. doi: 10.1016/j.vaccine.2011.10.036. Epub 2011 Nov 24.

PMID:
22120193
15.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
16.

Vaccination against herpes zoster in developed countries: state of the evidence.

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.

Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Review.

17.

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Langan SM, Smeeth L, Margolis DJ, Thomas SL.

PLoS Med. 2013;10(4):e1001420. doi: 10.1371/journal.pmed.1001420. Epub 2013 Apr 9.

18.

Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.

Johnson RW.

Aging Clin Exp Res. 2009 Jun;21(3):236-43. Review.

PMID:
19571648
19.

Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.

Betts RF.

J Am Acad Dermatol. 2007 Dec;57(6 Suppl):S143-7.

PMID:
18021866
20.

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.

Sanford M, Keating GM.

Drugs Aging. 2010 Feb 1;27(2):159-76. doi: 10.2165/10489140-000000000-00000. Review.

PMID:
20104941
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk